Search - tctmd.com

Displaying 81 - 100 of 163

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Shockwave Aortic Valve Remodeling: Experimental Findings and Future Clinical Applications

Presenter: Tamim Nazif, Steven J. Yakubov, Eberhard Grube

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Pilot Programs to Address Reduced TAVR Access in Underserved Populations and Communities

Presenter: Randolph P. Martin, Mark J. Russo, Aaron Horne, Jr.

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Early Degeneration of First Generation Sapien Valve Treated With Valve-in-Valve Evolut R Valve

Presenter: Howard C. Herrmann, Fabian Nietlispach, Cenap Undemir, MD

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

New Applications for the V8 Valvuloplasty Balloon

Presenter: Tamim Nazif, Steven J. Yakubov, Wesley R. Pedersen

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Exploring the Volume-Outcome Relationship With TAVR: Influences of New Devices and Crowd Learning

Presenter: Randolph P. Martin, Mark J. Russo

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

The "Family" of TRUE Balloons: Design Characteristics and Clinical Applications

Presenter: Tamim Nazif, Steven J. Yakubov, Susheel K. Kodali

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Recurrent Leaflet Thrombosis After Sapien 3 Valve-in-Valve TAVR

Presenter: Howard C. Herrmann, Fabian Nietlispach, Hasan Ahmad, MD

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Societal Impact of Access Restrictions to TAVR: Viewpoint From The Canadian Health Technology Assessment (HTA) Agency

Presenter: Randolph P. Martin, Mark J. Russo, Harindra Wijeysundera

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Subtotal Left Main Occlusion Two Days After Transcatheter Aortic Valve Replacement in Severe Bicuspid Aortic Stenosis

Presenter: Howard C. Herrmann, Fabian Nietlispach, Futoshi Yamanaka, MD

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Improved Temporary Transvenous Pacemakers: The BioTrace Tempo Lead

Presenter: Tamim Nazif, Steven J. Yakubov

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cases of Unusual Mechanisms of Coronary Occlusion During TAVR

Presenter: Omar Khalique

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Coronary Occlusion Following Self-Expandable Transcatheter Aortic Valve Replacement in Native Aortic Valve Regurgitation

Presenter: Howard C. Herrmann, Fabian Nietlispach, Mohamad Lazkani, MD

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Large Hole Transfemoral Closure III: The MANTA Device

Presenter: Nicolas M. Van Mieghem

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

TAVR Case Selection in the Real World: Based on Society Guidelines OR Risk Models OR Clinical and Anatomic Factors?

Presenter: Allan Schwartz, Stephan Windecker, Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

The New Syndrome of Delayed Coronary Occlusion (DCA) After TAVR: Frequency, Causes, and Outcomes

Presenter: Azeem Latib

June 21, 2018

Advertisement

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Shockwave Aortic Valve Remodeling: Experimental Findings and Future Clinical Applications

Pilot Programs to Address Reduced TAVR Access in Underserved Populations and Communities

Early Degeneration of First Generation Sapien Valve Treated With Valve-in-Valve Evolut R Valve

New Applications for the V8 Valvuloplasty Balloon

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Exploring the Volume-Outcome Relationship With TAVR: Influences of New Devices and Crowd Learning

UK All-Comers

The "Family" of TRUE Balloons: Design Characteristics and Clinical Applications

Recurrent Leaflet Thrombosis After Sapien 3 Valve-in-Valve TAVR

Societal Impact of Access Restrictions to TAVR: Viewpoint From The Canadian Health Technology Assessment (HTA) Agency

Evolut R Low-Risk

Subtotal Left Main Occlusion Two Days After Transcatheter Aortic Valve Replacement in Severe Bicuspid Aortic Stenosis

Partner 3 Low-Risk

Improved Temporary Transvenous Pacemakers: The BioTrace Tempo Lead

Cases of Unusual Mechanisms of Coronary Occlusion During TAVR

Coronary Occlusion Following Self-Expandable Transcatheter Aortic Valve Replacement in Native Aortic Valve Regurgitation

Large Hole Transfemoral Closure III: The MANTA Device

TAVR Case Selection in the Real World: Based on Society Guidelines OR Risk Models OR Clinical and Anatomic Factors?

The New Syndrome of Delayed Coronary Occlusion (DCA) After TAVR: Frequency, Causes, and Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content